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Impregnating a proteolytic substrate of specifity to viral envelope with a restriction enzyme cleaving the 
HIV genome could generate a novel line of microbicide. Web Cutter version 2.0 aimed at identifying 
which enzyme can cleave HIV-1 and 2 genomes in 10 or > cuts was employed. Computational analysis 
indicate that of 291, 17 (5.8%) enzymes had 10 or more cuts in the HIV- 1/SIVcpz genome as compared 
to 25 (8.9%) for HIV-2/SIVsmm with 6 enzymes (Eco-130I, EcoT141, ApoI, AcsI, BssTII, and StyI) having a 
mutual ability to cleave HIV-1 and 2 in 10 and more cuts. Although not a proteolytic enzyme, the 
surfactant Savvy/C31G (Cellegy) was identified as a safe and close candidate for our proteolytic 
substrate. With biochemical compound modeling, it is possible to stably impregnate the center of 
surfactant/detergent molecule with a natural product. The PREX Model may be explored to develop 
novel lines of microbicides aimed at preventing HIV and other viral STI transmission in humans 
 






Since the description of its first clinical case in Los Ange-
les (CDC, 1981), the global Human Immunodeficiency 
Virus/Acquired immunodeficiency Syndrome (HIV/AIDS) 
epidemic has soared to pandemic levels (Fanci, 1999; 
Joint UNAIDS/WHO, 1997; WHO: 1999; UNAIDS., 2004). 
The 2006 United Nations Joint Programme on HIV/AIDS 
(UNAIDS) report estimates that 38.6 million (33.4-46 
million) people worldwide were living with HIV at the end 
of 2005. An estimated 4.1 million (3.4-6.2) became newly 
infected with HIV and another 2.8 million (2.4-3.3) lost 
their lives (UNAIDS, 2006). 
There is still no cure, and current therapy serves only to 
ameliorate associated morbidity and prolong life (Ham-
mer et al., 2006; Bartlett et al., 2001). Although various 
novel therapy (Mayer et al., 2006; Gulick et al., 2006; 
Sansone et al., 2006; Pugach et al., 2006; Anastaso-
poulou et al., 2006; Norris et al., 2005; Norris et al., 2006; 
Davison et al.,  2006; Delmedico et al., 2006; Markowitz 
et al., 2006) and vaccine initiatives are in trial, no effective 
vaccine or cure is envisioned in the next 10 years (Global 
HIV prevention working group (GHWG), 2006).Over 60% 
of all HIV/AIDS cases occur in sub-Saharan Africa (25.8 
million), a region only accounting for 10% of the global 
human population. Majority of all these cases are sexual-
ly transmitted, with women being worst hit (UNAIDS, 
2006). This has prompted current prevention campaigns 
to emphasize the need for emancipating the African 
women (Green et al., 2002; Nantulya, 2002; Stover, 
2002; Stoneburner et al., 2000, 2002). 
Other efforts geared towards protecting the woman 
from HIV infection have concentrated on the development 
of microbicides; topical agents like creams or gels that 
can be applied to the vaginal/cervical/anal mucosa to 
prevent HIV transmission (GHWG, 2006).The Microbicide 
industry, according to the Alliance for Microbicide develo-
pment (AMD), is a fast growing one. As of today, microbi-
cidal candidates fall into four categories or a combination 
of categories, based on their mechanism of action: 1) 
Products that kill or inactivate infectious pathogens, 2) 
products that block fusion, that is, attachment of patho-
gens to the mucosal surface of target cells, 3) products 
that inhibit post fusion activity, and 4) products that 
enhance naturally occurring vaginal defense mechanisms 
(Stoneburner et al., 2000, 2002; Roddy et al., 1998; 
Mauck et al., 2004; Bax et al., 2002; Dhawan and Mayer, 
2006; HIV Vaccines and Microbicides Resource Tracking  




Table 1. Restriction enzymes cleaving HIV genome in 10 or more cuts. 
 
HIV subtype/(genome)/bps/N (%) 
enzymes 
No. cuts Enzymes: Number (Name) 
10 2 (BseRI, DraI), 
11 3 (BanII, Eco24I ,FriOI) 
13 3 (Eam1104I, EarI, Ksp632I) 
16 5 (BssT1I, Eco130I, EcoT14I, ErhI, StyI) 




/9037 base pairs/17 (5.8%) 
 
 
24 2 (AcsI, ApoI) 
10 9 (AccB1I, BanI, BshNI, DraII ,Eam1104I, EarI, Eco64I, EcoO109I, 
Ksp632I) 
11 9 (BssT1I, BstSFI, CfrI, EaeI, Eco130I, EcoT14I, ErhI, SfcI, StyI) 
12 5 (BstYI, MflI, MspA1I, NspBII, XhoII) 
HIV-2/SIVssm/ 
(A.GM.x.MCN13_AY509259)/ 
9713 base pair/25 (8.9%) 
 




Working Group (HVMRTWG), 2000, 2001, 2002, 2003, 
2004, 2005).  
Most of the prototypes of these groups; although 
demonstrate by clinical trials to be safe, have not out 
rightly stood the tests of efficacy, a fact that underlines 
the need to develop novel prototypes, or new genera-
tions. Combinations Microbicides, with or without a new 
product, has been stated as a possibility for creating an 
effective microbicide against HIV transmission. 
A combination of an HIV envelope/Capsid lysing 
specific proteolytic enzyme/substrate-like agent (sparing 
the host mucosal squamo-columnar epithelium) impreg-
nated with restriction enzyme(s) with demonstrated 
potency against the HIV proviral genome could form 
basis for an effective, novel line of microbicides. Results 
of our search for precursors of PREX-1979, the first 
prototype of these “5th generation” proteo-restriction 





Computational analysis employing Web cutter version 2.0 
(www.http://rna.lundberg.gu.se/cutter2/) was used to search for 
restriction enzymes cleaving both HIV-1 and 2 proviral DNA. The 
HIV1 and 2 whole genome [the 9037 base pair HIV-1/SIVcpz 
(A1.BY.97.97BL006_AF193275), 9713 base pair and HIV-2/SIVssm 
(A.GM.x.MCN13_AY509259)] sequence alignments obtained from 
the HIV gene sequence database (www.hiv.lanl.gov/content/hiv-
db/ALIGN_CURRENT/ALIGN-INDEX.html) were fed into web cutter 
version 2.0 preset to recognize bacteria restriction enzymes 
cleaving 10 or > cuts/times by recognizing 6 or > base pair nucleo-
titide palindromic sequences. The feasibility of creating stable and 
sustainable chemical/H+ bonds between any two of the substrates 
above was hypothetically examined. 
 
 
RESULTS AND DISCUSSION 
 
Of the 291 restriction enzymes analysed, 17 (5.8%) 
enzymes had 10 or more cuts in the HIV-1/SIVcpz geno-
me as compared to 25 (8.9%) for HIV-2/SIVssm. Six 
enzymes (Eco-130I, EcoT14I, ApoI, AcsI, BssTII, and 
StyI) exhibited a mutual ability to cleave both HIV-1 and 2 
in 10 or more cuts (Table 1).  
Although not a proteolytic enzyme, the mircobicide 
agent SAVVY/C31G (Cellegy) was identified as an exist-
ing, and extensively studied compound with the closest 
properties defined above (Table 2). A surfactant, SAVVY, 
is one of the group prototypes to reach third clinical trials. 
A product of Cellegy pharmaceutical, 1.0% formulations 
of Savvy have been demonstrated to have an approved 
safety profile for repeated applications both in animal 
(Patton et al.,  2006) and human trials (GHWG, 2006). 
Since no such proteolytic enzyme was found and 
SAVVY is a surfactant, a model bonding SAVVY with a 
restriction enzyme was conducted. Surfactants, with 
chemical bonds, tend to repel natural agents with hydro-
gen bonds. However, it is possible to impregnate the cen- 
tre of a surfactant with a natural compound such as 
restriction enzyme. 
Results of the computational assay reveal that as far as 
susceptibility to restriction enzymes cutting 10 or more 
times goes, the smaller HIV-1 genome [The 9037 base 
pair HIV-1/SIVcpz (A1.BY.97.97BL006_AF193275)] is 
less susceptible with 17 (5.8%) restriction enzymes than 
the bigger HIV-2 genome[the 9713 base pairHIV-
2/SIVssm (A.GM.x.MCN13_AY509259)] with 25(8.9%) 
restriction enzymes. However, HIV-1 is the most preva-
lent subtype globally, especially in the worst hit regions of 
sub-Saharan Africa. Regardless, we identified 6 restric-
tion enzymes with mutual potency against HIV-1 and 2; 
Eco-130I, EcoT14I, ApoI, AcsI, BssTII, and StyI, and 
these will serve as the restriction enzyme component of 
PREX-1979. Both these enzymes and their genes, are 
already isolated, and can readily be purchased from 
specialised biochemical companies. 
Savvy/C31G is a first class, third generation microbi-
cide, developed by Cellergy pharmaceuticals. This gene-
ration of microbicides are structurally 
detergents/surfactants, and act by  destabilising  the  HIV  




Table 2. Classification of current microbicides. 
 
1. Compounds and products that kill or inactivate pathogens. 
Product Category Examples 
Surfactants/detergents Nonoxynol-9, octoxynol-9, benzalkonium chloride, 
menfegol, Savvy (C31G), sodium dodecyl sulfate 
(SDS), sodium laurel sulfate (SLS), chlorhexidene 
Peroxidases/peroxides Haloperoxidases, halides 
Lipids Hydrogels, synthetic lipids adapted from human 
breast milk lipids, hemicholinium and related lipids 
Plant extracts Praneem polyherbal suppository, gossypol 
Antimicrobial peptides (See compounds that enhance vaginal defense 
mechanisms) 
Monoclonal antibodies (See compounds that enhance vaginal defense 
mechanisms) 
Acidic buffers (See compounds that enhance vaginal defense 
mechanisms) 
2. Inhibitors of pathogen attachment to target cells. 
Product Category Examples 
Fusion blockers specifically targeting HIV surface 
proteins or HIV receptors 
gp-41 inhibitor (T-20), CCR-5 inhibitor 
Other fusion blockers (often active against multiple 
organisms) 
Cyanovirin-N (CV-N), beta-lactoglobulin (B69), 
B195/CAP (cellulose acetate phthalate) 
3. Non-specific blockers (active against multiple 
organisms) 
Sulfated/sulfonated polymers (Carraguard, Emmelle, 
Ushercell, Pro-2000), Q-2 bioadhesive 
polysaccharide, other charged polymers 
4. Inhibitors of post-fusion activity. 
Product Category Examples 
Nucleoside/tide RT inhibitors Tenofovir (PMPA), zidovudine (AZT) 
Non-nucleoside/tide RT inhibitors Carboxanilides (UC781), nevirapine 
Protease inhibitors Doxovir (CTC-96) 




viral envelope. These agents have been widely studied 
for their safety and efficacy (Patton et al., 2006). Savvy at 
1.0% concentrations, has been demonstrated to be a 
safe profile for repeated vaginal application, both in ani-
mals, and human. Phase 3 clinical trials in West Africa 
were, however, halted by external monitors’ findings of 
undemonstratable efficacy in humans within the study 
group versus control; findings that could have resulted 
from study design. Regardless, Savvy is a potential 
candidate for the proteolytic component of PREX, and by 
itself, or in a modified pattern, may serve the function of 
PREX’s background component destabilising the HIV 
envelope. 
Most current microbicdes have been demonstrated by 
clinical trials to have safe profiles at particular concen-
trations for use in humans, but all have yet to stand the 
test of efficacy in terms of preventing HIV transmission 
sexually. Of late, combining existing microbicides, with or 
without new products, has thus been stated to be a 
possible route for creating an effective microbicide 
against sexual transmission of HIV (Dhawan and Mayer, 






A protocol aimed at biochemically engineering PREX-
1979, the first prototype of these could be 5th generation 
of microbicides, has been designed. Combinations of exi-
sting microbicides, with or without a new component, may 
offer better protective properties against HIV transmis-
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